We previously reported antigen frequency differences for HLA-DR4 and HLA-DRw6 between idiopathic dilated cardiomyopathy (IDC) patients and healthy controls in a pilot study. To confirm these findings, we undertook an independent study with a prospective hypothesis regarding the frequencies of DR4 and DRw6; typing for a second family of class II antigens (HLA-DQ) was included because of the proximity of the DQ loci to the DR loci and the strong linkage disequilibrium between some of the DR and DQ alleles. Comparing a new consecutive series of IDC patients (n=41) and healthy blood bank controls (n=53), we confirmed an increase of DR4 antigen frequency in patients (491% versus 21%, p<O.OOS). A trend toward decreased expression of DRw6 among patients was also noted (10%1 of patients versus 23% of controls). HLA-DQw4 was significantly elevated in patients compared with controls (27% versus 6%, p<0.005; relative risk, 6.1; etiologic fraction, 0.22). We identified the combined DR4-DQw4 haplotype in five of 41 Caucasian IDC patients (12%) and none of 53 controls (p<0.007). A comparison of specific antigen frequencies between the preliminary and validation studies did not reveal significant differences; therefore, the data from the two studies were examined in combination. For the combined studies, DR4 was elevated (51% versus 27% in controls, p<0.001), and DRw6 was decreased (9%o versus 24% in controls, p<0.01). The relative risk for DR4 was 2.8, and the etiologic fraction was 0.33. In this study, the DR4-DQw4 haplotype bears an indeterminately high risk for disease; the presence of DR4, DQw4, or both antigens was found in 26 of 41 IDC cases (63%) compared with 14 of 53 controls (26%) (p<0.001). Meta-analysis of the exploratory and validation studies in combination with all reported studies comparing the frequency of HLA-DR antigens in IDC patients and controls was performed. This overview indicated that for all five studies, there is a significant increase in the frequency of HLA-DR4 in cases of IDC (overall odds ratio, 2.06; 98% confidence interval, 1.61-2.65; p <0.0001). In conclusion, we have verified HIA-DR4 involvement in IDC and suggested an additional association with DQw4. The meta-analysis of reported studies confirms that the DR4 association can be replicated in several different patient populations. Thus, in a portion of IDC cases, predisposing genetic factors linked to immunoregulatory loci appear to be present. (Circulation 1991;83:515-522) Idiopathic dilated cardiomyopathy (IDC) is a sponses and/or regulatory mechanisms include dedisease of uncertain origin for which immune creased natural killer cell activity (an antiviral abnormalities, possibly in conjunction with a defense mechanism),' functional deficit in suppressor viral infection, are suspected but unproven. Abnorcell activity,2,3 and humoral and cellular autoimmune malities suggestive of dysfunctional immune rereactivities against myocytes
We previously reported antigen frequency differences for HLA-DR4 and HLA-DRw6 between idiopathic dilated cardiomyopathy (IDC) patients and healthy controls in a pilot study. To confirm these findings, we undertook an independent study with a prospective hypothesis regarding the frequencies of DR4 and DRw6; typing for a second family of class II antigens (HLA-DQ) was included because of the proximity of the DQ loci to the DR loci and the strong linkage disequilibrium between some of the DR and DQ alleles. Comparing a new consecutive series of IDC patients (n=41) and healthy blood bank controls (n=53), we confirmed an increase of DR4 antigen frequency in patients (491% versus 21%, p<O.OOS). A trend toward decreased expression of DRw6 among patients was also noted (10%1 of patients versus 23% of controls). HLA-DQw4 was significantly elevated in patients compared with controls (27% versus 6%, p<0.005; relative risk, 6.1; etiologic fraction, 0.22). We identified the combined DR4-DQw4 haplotype in five of 41 Caucasian IDC patients (12%) and none of 53 controls (p<0.007). A comparison of specific antigen frequencies between the preliminary and validation studies did not reveal significant differences; therefore, the data from the two studies were examined in combination. For the combined studies, DR4 was elevated (51% versus 27% in controls, p<0.001), and DRw6 was decreased (9%o versus 24% in controls, p<0.01). The relative risk for DR4 was 2.8, and the etiologic fraction was 0.33. In this study, the DR4-DQw4 haplotype bears an indeterminately high risk for disease; the presence of DR4, DQw4, or both antigens was found in 26 of 41 IDC cases (63%) compared with 14 of 53 controls (26%) (p<0.001). Meta-analysis of the exploratory and validation studies in combination with all reported studies comparing the frequency of HLA-DR antigens in IDC patients and controls was performed. This overview indicated that for all five studies, there is a significant increase in the frequency of 16 Furthermore, it has been demonstrated in mice that during the fetal development of the immune system, the expression of a particular class II allele is a controlling factor in the elimination of reactive T cell clones specific for that particular allele. The end result of the elimination of these T cell clones is self-tolerance in the adult animal. 17 Because of the importance of these immunoregulatory and tolerogenic roles of the class II antigens, they Consecutively identified patients fulfilling previously established diagnostic criteria for IDC19,25 were entered into the study. These criteria included a dilated left ventricular chamber of idiopathic cause with an ejection fraction of less than 45%. Controls consisted of consecutively tested healthy blood bank donors. The genetic heritage of our population base is largely Northern European (Anglo-Scandinavian). The study was approved by the institutional review board, and all subjects were entered into the study after informed consent was obtained.
Lymphocyte Isolation
Lymphocytes were obtained by Ficoll-Hypaque (Pharmacia, Piscataway, N.J.) density gradient centrifugation. Heparinized blood (approximately 20 ml) was diluted 1:1 with McCoy's 5A tissue culture medium overlaid on 10-15 ml Ficoll-Hypaque in a conical centrifuge tube. The mixture was centrifuged at 400g for 40 minutes. The mononuclear cell population was removed from the plasma-Ficoll-Hypaque interface and washed three times.
Purified B lymphocytes for DR and DQ typing were obtained by treatment of the mononuclear cells with B Quick B-lymphocyte isolation reagent (One Lambda, Inc., Los Angeles). The B lymphocytes were adjusted to a final concentration of 1-2 x 106/ml in serum-free McCoy's. Relative risk (RR)=(axb)l(cxd). Etiologic fraction=(RR-1/RR)(a/a+b).
Cytotoxicity Assay
HLA-DR and HLA-DQ typings were done by the microcytotoxicity method of Terasaki et al. 26 Briefly, 1 gd of a lymphocyte suspension was added to each well of a typing tray (One Lambda, Inc.) and incubated at 37°C for 60 minutes. After the primary incubation, 5 ,u of rabbit complement was added to each well, and the tray was incubated at room temperature for 2 hours. Dead cells were stained by adding 2 ,ul eosin Y (5%) and fixing in formalin. The percent viability was visually assessed with an inverted phase-contrast microscope.
Haplotype Assignments
Where possible, HLA-DR and HLA-DQ alleles were presumptively assigned to specific haplotypes using known DR and DQ associations.27
Presentation and Statistical Analysis of HLA-DR and HLA-DQ Typing Results
Results are reported as both the percentage of patients positive for each specificity and the number of times a particular antigenic specificity was identified. The sum of all antigens identified may be slightly less than the number of antigen-bearing haplotypes in the study (twice the number of patients) because of untypeable or "blank" specificities or homozygosity for a particular allele. Comparison between patients and control subjects used 2x2 contingency tables as illustrated in Table 1 The meta-analysis of HLA-DR4 typing combining the results from the present study and four other centers was performed using the method of combining the logarithms of the odds ratios as described by Fleiss22 and DerSimonian and Laird. 23 In this procedure, the odds are defined as the ratio of the DR4 positive to the DR4 negative subjects, and the odds ratio is the ratio of the odds obtained for the patient sample to the odds obtained for the control group. For the meta-analysis, the log of the odds ratio, the standard error of the log odds ratio, and a weighting factor (based on the inverse of the standard error) are obtained for each individual study. Then, the weighted averages of the log odds ratio and log standard error are obtained, and these measures are used to construct a test for homogeneity of the odds ratios obtained for the different studies. These measures are also used to construct a global test of association for the weighted average of the odds ratio. The test of association assesses the significance of the departure from the null hypothesis (odds ratio, 1) and a 95% confidence interval for the odds ratio.
Results

Results of Validation Study of DR Antigen Frequencies in Idiopathic Dilated Cardiomyopathy
The results for the validation study for IDC patients and concurrent controls are shown in Table 2 .
In the validation study, the association of DR4 with IDC was confirmed. For IDC patients, 49% were positive for DR4 compared with 21% of the controls (p<0.005). The frequency of the DRw6 antigen was 
Combined Studies
Because the distribution of DR4 and DRw6 antigen frequencies in patient and controls in the validation and exploratory studies were generally similar, the results from both studies were combined, and the results of the combined series are presented in Table  4 . The overall antigen frequency for DR4 was 27% for controls and 51% for patients (p<0.001). (This difference is significant even if a further correction for multiple comparisons is made; p<0.01). The antigen frequency of DRw6 was 24% for controls and 9% for patients (p<0.01, uncorrected; p<0.1, corrected). DR1 and DRw8 were reduced compared with controls (13% versus 24% and 7% versus 11%, respectively) in the combined series, but these differences were not significant. Relative Risk, Etiologic Fraction, and
Preventive Fraction
The relative risk and etiologic and preventive fractions were calculated for DR4, DRw6 (combined studies), DQw4, and DR4/DQw4 (validation study) as described in "Methods" and given in Table 5 . The relative risk (increased probability of developing the disease in the presence of compared with the absence of a particular allele) for DR4 was 2.8, and the etiologic fraction (the percentage of all cases of the disease attributable to the presence of a particular allele) was 0.33. For DQw4, the relative risk was 6.1, and the etiologic fraction was 0.22. The combination of DR4 and DQw4 on a single haplotype (n=5) was associated with an indeterminately ("infinitely") high risk for disease in that this haplotype was not identified in any control subjects. The etiologic fraction of DR4/DQw4, however, was only 0.12. The relative risk for DRw6 was 0.31, indicating that the presence of this allele was associated with a decreased risk for the disease compared with DRw6-negative individuals. The Tables 7  and 8 . The odds ratios and the 95% confidence intervals of the odds ratios of the HLA-DR4 frequencies (comparing IDC patients with controls) are presented for our study and the other four studies in Table 7 . These data show a range of sample odds ratios of 1.05-3.23; combining all studies (Table 8) , the odds of having a DR4 allele is 2.06 (95% confidence intervals, 1.61-2.65; p< 0.0001) in patients with IDC. A test for homogeneity indicated that the results from the different studies were similar, with the exception of the Zerbe et a129 study. Thus, the meta-analysis was performed both with and without inclusion of the Zerbe et al data (Table 8) . In both cases, the test of association was significant beyond the 0.0001 level, indicating that the overview of studies verifying an increase in the frequency of HLA-DR4 associated with IDC compared with healthy local controls can be replicated over a broad geographical range in populations of European extraction. No other associations of IDC with other HLA-DR alleles emerged in the overview. Discussion IDC is undoubtedly a heterogeneous disease in which multiple factors may be contributory, including infectious, toxic, and genetic factors. In this regard, it is not surprising that we were not able to find evidence for genetic predisposition in all cases of IDC examined. However, our findings indicate that in a certain number of cases (approximately one third to one half of cases as suggested by etiologic fractions), genetically determined immunoregulatory factors associated with MHC antigens in our population of European (primarily Anglo-Scandinavian) descent may be involved in pathogenesis. Our validation study confirmed the involvement of DR4 in some cases as predicted by our preliminary study. The association with HLA-DR4 was further replicated by meta-analysis of other studies.
Meta-analysis is the statistical analysis of a collection of results in an effort to objectively combine the results of different studies.23 There are several advantages to the use of such an approach. An individual study may not be sufficiently large to warrant certain conclusions. This is particularly true for studies such as these in which multiple variables (i.e., antigen specificities) are analyzed simultaneously, thus increasing the probability of chance associations. Thus, the weight and thereby the significance of a finding are increased by the increased sample size obtained by combining studies. In addition, a finding is given particular significance if it is replicated by several independent observations. Finally, conditions the etiologic fraction may be used to provide an estimate of the degree of linkage disequilibrium between the marker and the locus of the disease susceptibility gene. If we assume the presence of such a disease susceptibility gene located on chromosome 6, as suggested by available evidence, then calculating the etiologic fractions for DR4 and DQw4 gives values of similar magnitude (DR4, 0.32; DQw4, 0.25). Thus, the more specific location for the putative disease-causing gene is not readily suggested. However, several possibilities should be considered. First, the fact that the combined DR4-DQw4 haplotype was identified in approximately 13% of patients but was not found in healthy controls could indicate that the particular "disease locus" in question lies between the DR and DQ loci and that the particular disease-producing allele is in linkage disequilibrium with both DR4 and DQw4. In this case, it would appear in very high frequency on haplotypes carrying both the DR4 and DQw4 specificities, as was observed. It would fail to appear only when a crossover event occurred between two haplotypes, one bearing DR4 and the other DQw4, but each without the gene in question. Another possibility is that the "disease gene" is actually associated with a subtype of DR4 that is defined by its linkage with DQw4 (i.e., the DRw15 subtype27). In this case, the disease gene would be linked to DR4, but the DR4 etiologic fraction we calculated would be an average of all DR4 subtypes-both those linked to the disease and those not associated with it. This would result in an artificially low calculated etiologic fraction for DR4, indicating a weaker degree of linkage than actually exists. Finally, the potential contribution of two genes in the pathogenesis of the disease must be considered. In this case, one associated with DR4 and one associated with DQw4 could be postulated. Such a situation has been described for insulin-dependent diabetes mellitus, in which the relative risks associated with the two alleles are each less than 1.0 when they occur separately. However, when they occur together on a single haplotype, the relative risk increases to 12.1. 39 The contribution of two class II alleles in the development of disease may involve the process of interisotypic pairing of class II peptides from different loci to form heterodimers. Lotteau and coworkers40 have recently described a human cell line in which DRca/DO heterodimers were expressed.
In this system, the expression of the DRa/DOQ3 heterodimers was associated with a high ratio of DRa messenger RNA (mRNA) to DRJ3 mRNA. The extent of this type of interisotypic pairing or the implications for antigen presentation and disease associations are not known, but intriguing possibilities are presented.
At this time, it is unclear why specific antigencontaining haplotypes are associated with disease development, in this or other diseases with HLA class II associations. However, the class II antigens function in the presentation of foreign antigen to T helper lymphocytes, and it is conceivable that abnormal antigen presentation could lead to an autoim-mune response. Consistent with this hypothesis, in IDC, investigators have identified in the sera of patients antibodies to human cardiac fl-receptors that are capable of inhibiting ligand binding.7 Furthermore, the occurrence of these antibodies appears to correlate with DR4-containing haplotypes.4' These observations begin to focus attention on the actual pathogenic mechanisms and may eventually explain the increased risk associated with certain haplotypes.
In conclusion, these studies provide evidence for an association between certain HLA antigens and IDC. The association between DR4 and disease observed in an exploratory study has been validated in this second, prospective study. This study also suggested the involvement of DQw4-carrying haplotypes in the pathogenesis of the disease. The relation of DRw6 to prevention of IDC is suggestive but deserves further confirmation. The strong statistical correlation of DR4 with IDC observed in an overview of all published studies lends further weight to the validity of this observation. Overall, these findings are consistent with the hypothesis that IDC may arise in part from abnormal immune regulation, perhaps in conjunction with an infectious process. Although the full extent of these antigen associations and the specific pathogenic mechanisms are at present unknown, the evidence thus far is sufficiently compelling to warrant further investigation.
